AQP4 and myasthenia gravis: Indeed, complement activation is recognized as a major pathogenic or contributing factor in neuromyelitis optica spectrum disorders (NMOSDs) and myasthenia gravis (MG), where AABs form stable surface complexes on aquaporin-4 (AQP4) or acetylcholine receptors (AChRs), respectively [76,77,78].